Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:FHTX NASDAQ:MGX NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$5.83-3.8%$4.90$2.54▼$10.00$434.39M0.51560,527 shs412,662 shsFHTXFoghorn Therapeutics$5.19-1.7%$5.40$2.94▼$10.25$293.39M3.0582,826 shs82,067 shsMGXMetagenomi$1.86-1.6%$2.02$1.23▼$4.92$69.81M-0.16163,342 shs129,247 shsOCGNOcugen$1.07$1.04$0.52▼$1.29$312.76M4.161.62 million shs1.71 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals0.00%-5.36%+7.37%+36.85%+14.31%FHTXFoghorn Therapeutics0.00%-10.05%+4.22%+18.22%-46.60%MGXMetagenomi0.00%-2.62%0.00%+29.17%-31.11%OCGNOcugen0.00%+3.88%+1.90%-7.76%-11.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$5.83-3.8%$4.90$2.54▼$10.00$434.39M0.51560,527 shs412,662 shsFHTXFoghorn Therapeutics$5.19-1.7%$5.40$2.94▼$10.25$293.39M3.0582,826 shs82,067 shsMGXMetagenomi$1.86-1.6%$2.02$1.23▼$4.92$69.81M-0.16163,342 shs129,247 shsOCGNOcugen$1.07$1.04$0.52▼$1.29$312.76M4.161.62 million shs1.71 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals0.00%-5.36%+7.37%+36.85%+14.31%FHTXFoghorn Therapeutics0.00%-10.05%+4.22%+18.22%-46.60%MGXMetagenomi0.00%-2.62%0.00%+29.17%-31.11%OCGNOcugen0.00%+3.88%+1.90%-7.76%-11.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 3.00Buy$15.00157.29% UpsideFHTXFoghorn Therapeutics 3.17Buy$10.67105.52% UpsideMGXMetagenomi 3.00Buy$10.00437.63% UpsideOCGNOcugen 3.00Buy$6.00460.75% UpsideCurrent Analyst Ratings BreakdownLatest MGX, CRVS, FHTX, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025MGXMetagenomiHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $12.008/4/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AFHTXFoghorn Therapeutics$22.60M12.98N/AN/A($0.82) per share-6.33MGXMetagenomi$52.29M1.33N/AN/A$6.28 per share0.30OCGNOcugen$4.05M77.22N/AN/A$0.10 per share10.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)FHTXFoghorn Therapeutics-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)MGXMetagenomi-$78.06M-$2.36N/AN/AN/A-257.99%-37.84%-27.15%11/12/2025 (Estimated)OCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)Latest MGX, CRVS, FHTX, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MGXMetagenomi-$0.68-$0.54+$0.14-$0.54$7.72 million$8.51 million8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/A8/5/2025Q2 2025FHTXFoghorn Therapeutics-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 million8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A8.918.91FHTXFoghorn TherapeuticsN/A2.622.62MGXMetagenomiN/A6.366.36OCGNOcugen9.181.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%FHTXFoghorn Therapeutics61.55%MGXMetagenomiN/AOCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals31.30%FHTXFoghorn Therapeutics7.58%MGXMetagenomi17.80%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3074.51 million51.19 millionOptionableFHTXFoghorn Therapeutics12056.53 million52.25 millionOptionableMGXMetagenomi23637.53 million30.85 millionN/AOCGNOcugen80292.30 million279.77 millionOptionableMGX, CRVS, FHTX, and OCGN HeadlinesRecent News About These CompaniesOcugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 Million1 hour ago | quiverquant.comQOcugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea1 hour ago | globenewswire.comNuveen LLC Takes Position in Ocugen, Inc. $OCGNSeptember 7, 2025 | marketbeat.comOcugen CEO to Speak at Investor Conferences in New York and MunichSeptember 6, 2025 | msn.comOcugen Enters Subscription Agreement with Carisma TherapeuticsSeptember 5, 2025 | tipranks.comCarisma Therapeutics stock soars after merger agreement with OcugenSeptember 3, 2025 | au.investing.comOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025September 2, 2025 | finance.yahoo.comOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025September 2, 2025 | globenewswire.comGMT Capital Corp Grows Position in Ocugen, Inc. $OCGNSeptember 1, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Stock Price Up 3% - Here's WhyAugust 27, 2025 | marketbeat.comOcugen (OCGN) Upgraded to Buy: Here's What You Should KnowAugust 26, 2025 | zacks.comOcugen IncAugust 25, 2025 | edition.cnn.comOcugen reports EMA positive advice for acceptability of OCU410STAugust 13, 2025 | msn.comOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to ...August 13, 2025 | bakersfield.comBOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt DiseaseAugust 13, 2025 | globenewswire.comOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | manilatimes.netMOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | globenewswire.comOcugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson InvestorsAugust 8, 2025 | quiverquant.comQOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 8, 2025 | globenewswire.com3OCGN : Demystifying Ocugen: Insights From 5 Analyst ReviewsAugust 4, 2025 | benzinga.comOcugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call TranscriptAugust 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGX, CRVS, FHTX, and OCGN Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$5.83 -0.23 (-3.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.96 +0.13 (+2.23%) As of 09/12/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Foghorn Therapeutics NASDAQ:FHTX$5.19 -0.09 (-1.70%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.18 -0.01 (-0.10%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Metagenomi NASDAQ:MGX$1.86 -0.03 (-1.59%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.89 +0.03 (+1.61%) As of 09/12/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Ocugen NASDAQ:OCGN$1.07 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+0.56%) As of 06:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
